Actively Recruiting
Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases
Led by Susanne Rogers · Updated on 2026-03-04
200
Participants Needed
10
Research Sites
335 weeks
Total Duration
On this page
Sponsors
S
Susanne Rogers
Lead Sponsor
U
University of Basel
Collaborating Sponsor
AI-Summary
What this Trial Is About
The research question is whether a single fraction of preoperative radiosurgery can reduce the incidence of leptomeningeal disease 12 months following resection of a brain metastasis (BM) as compared with 5 fractions of postoperative stereotactic radiotherapy.
CONDITIONS
Official Title
Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent
- Willingness to follow study procedures and be available throughout the study
- Age 18 years or older
- Karnofsky performance status of 60 or higher
- Histological confirmation of malignant primary or metastatic tumor
- Ability to take steroids
- No contraindication to MRI
- MRI diagnosis of a clearly defined contrast-enhancing brain metastasis up to 4.0 cm planned for surgical removal
- Up to 3 additional brain metastases suitable for radiosurgery
- Estimated survival longer than 12 months
- Platelet count above 100/ml, INR below 1.3, and hemoglobin above 7.5 g/dL
You will not qualify if you...
- Radiosensitive tumors such as germ cell tumors, lymphoma, or multiple myeloma
- More than 10 mm midline brain shift or signs of raised intracranial pressure requiring urgent surgery
- More than 4 brain metastases or the target metastasis larger than 4.0 cm
- More than one metastasis needing surgical removal
- Leptomeningeal disease in cerebrospinal fluid or on MRI unless localized and treatable with surgery and radiation
- Prior brain radiation therapy including radiosurgery or whole brain radiation
- Previous surgical removal of primary or secondary brain tumors
- Previous diagnosis of non-meningioma brain tumors
- Recent radionuclide therapy within 30 days
- Recent anti-VEGF therapy within 6 weeks
- Unable to tolerate radiosurgery immobilization or treatment
- Unable to give informed consent
- Pregnant or breastfeeding
- Women of childbearing potential unwilling to use effective contraception for at least 6 months after radiation
- Men unwilling to use effective contraception for 3 months after radiation
- Unlikely to comply with study protocol and follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Tirol Kliniken Innsbruck
Innsbruck, Austria, 6020
Active, Not Recruiting
2
Knappschaft Kliniken, Universitätsklinikum Bochum GmbH
Bochum, Germany
Actively Recruiting
3
UKGM-Giessen
Giessen, Germany
Actively Recruiting
4
Universitätsklinikum Schleswig Holstein
Kiel, Germany, 24103
Actively Recruiting
5
Kantonsspital Aarau
Aarau, Canton of Aargau, Switzerland, 5001
Actively Recruiting
6
Inselspital, Universitätsklinik für Radio-Onkologie
Bern, Freiburgstrasse, Switzerland, 3010
Actively Recruiting
7
Kantonsspital Graubünden
Chur, Switzerland, 7000
Actively Recruiting
8
Luzerner Kantonsspital
Lucerne, Switzerland, 6000
Actively Recruiting
9
Kantonsspital St. Gallen
Sankt Gallen, Switzerland, 9000
Actively Recruiting
10
Kantonsspital Winterthur
Winterthur, Switzerland, 8400
Actively Recruiting
Research Team
S
Susanne Rogers, MD PhD
CONTACT
O
Oliver Riesterer, Prof.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here